What is ARA-290?
ARA-290 is a peptide fragment modeled after the tissue-protective domain of erythropoietin (EPO). While EPO is primarily known for stimulating red blood cell production (hematopoiesis), it also possesses powerful anti-inflammatory and neuroprotective properties.
Researchers engineered ARA-290 to isolate these protective effects. By removing the hematopoietic domain, ARA-290 can be used in research to treat chronic pain and inflammation without the risk of increasing red blood cell counts or thickening the blood.
⚗️ Key Research Facts
- Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Primary Target: Innate Repair Receptor (IRR)
- Major Indication: Neuropathic Pain (SFN)
- Status: Investigational Compound
Mechanism: The Innate Repair Receptor (IRR)
The Innate Repair Receptor (IRR) is a specialized receptor complex that is only expressed in tissues undergoing stress, injury, or inflammation. Unlike standard receptors that are always active, the IRR acts as a "emergency beacon" for tissue repair.
Selective Binding
ARA-290 binds selectively to the IRR heteromer. Once activated, it triggers a powerful signaling cascade that suppresses the production of pro-inflammatory cytokines like TNF-α and IL-6. Simultaneously, it activates anti-apoptotic pathways that prevent cell death in damaged nerves.
Non-Hematopoietic
Because ARA-290 does not bind to the classic EPO homodimer receptor, it avoids the side effects associated with EPO, such as increased hematocrit or cardiovascular strain, making it a significantly safer candidate for chronic inflammatory research.
Small Fiber Neuropathy Research
Small Fiber Neuropathy (SFN) is a condition where the small, unmyelinated nerve fibers that carry pain and temperature signals are damaged. This often results in "burning" pain, tingling, and autonomic dysfunction.
Nerve Fiber Regeneration
In clinical trials (Phase II), ARA-290 has demonstrated the ability to not only reduce pain scores but actually increase corneal nerve fiber density. This suggests that the peptide may facilitate actual structural repair of the nervous system, rather than just masking symptoms.
- Sarcoidosis SFN: Significant improvements in neuropathic symptom scores.
- Diabetic Neuropathy: Reduced HbA1c levels and improved wound healing in preclinical models.
- Autoimmune Pain: Broad applications in fibromyalgia and complex regional pain syndrome research.
Anti-Inflammatory Action
Chronic inflammation is the root of many neurodegenerative and metabolic diseases. ARA-290 acts as a molecular "off switch" for the innate immune system's overactive response.
Neuroprotection
Protects neurons from oxidative stress and metabolic damage in ischemic research models.
Cytokine Suppression
Reduces the activation of macrophages and microglia, the primary drivers of neuro-inflammation.
Research Protocols & Dosing
- Administration: Subcutaneous injection.
- Trial Dose: Typically 4 mg (4,000 mcg) daily or 3 times per week.
- Cycle Duration: Clinical research often utilizes 28-day cycles to observe improvements in nerve density.
- Storage: Lyophilized powder should be stored in the freezer. Reconstituted solution must be refrigerated.
Frequently Asked Questions
Does ARA-290 increase red blood cells?
No. Research confirms that ARA-290 does not interact with the bone marrow receptors that stimulate erythropoiesis, avoiding the cardiovascular risks of EPO.
Can ARA-290 help with nerve damage?
Preliminary research suggests ARA-290 can stimulate the regrowth of small nerve fibers, making it a primary focus for researchers studying SFN and diabetic neuropathy.
Where to buy ARA-290 in Canada?
Nūmira Peptides provides high-purity, laboratory-tested ARA-290 for research use across North America. Shop ARA-290 →
